N/A
Completed N=15
Intravenous Interferon During Liver Transplant
Source: ClinicalTrials.gov NCT01192698 ↗Enrolled (actual)
15
Serious AEs
20.0%
Results posted
Aug 2017
Primary outcomePrimary: HCV RNA Result — 924,082; 3,731,749 IU/ml
Summary
The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation. The hypothesis is that patients who receive ribavirin immediately before transplant and intravenous interferon alfa 2b during the anhepatic phase(while the liver is removed)will have sustained virologic response post liver transplant.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY HCV RNA Result |
924,082; 3,731,749 | — |
Eligibility Criteria
Inclusion Criteria
- liver transplant for hepatitis c
Exclusion Criteria
- allergy to interferon
Data sourced from ClinicalTrials.gov (NCT01192698). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.